Related Experiment Video
Updated: Jun 23, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy
Neda Slade1, Ute M Moll, Branko Brdar
1Division of Molecular Medicine, Ruder Bosković Institute, Zagreb, Croatia. slade@irb.hr
Abstract:
The activation of protooncogenes and inactivation of tumor suppressor genes are considered to be the main molecular events in the multistep process of carcinogenesis. Mutations of the TP53 tumor suppressor gene have been found in nearly all tumor types and are estimated to contribute to more than 50% of all cancers. Most mutations lead to the synthesis of highly stable, inactive proteins that accumulate in the nucleus of cancer cells. Among the 393 codons of the human p53 gene, 222 are targets of 698 different types of mutations. Alterations of codons 175, 248, 273 and 282 correspond to 19% of all mutations and are considered general hot spot mutations. Dietary exposure to aristolochic acid (AA), an established nephrotoxin and human carcinogen found in all Aristolochia species was shown to be the causative agent of aristolochic acid nephropathy (previously called Chinese herbs nephropathy). This syndrome is characterized by proximal tubular damage, renal interstitial fibrosis, slow progression to the end stage renal disease and a high prevalence of upper urinary tract urothelial carcinoma (otherwise a highly unusual location). AA preferentially binds to purines in DNA and is associated with a high frequency of A-->T transversions in the p53 gene. Rats treated with AA develop A:T-->T:A mutations in codon 61. The pathological and clinical features of endemic (Balkan) nephropathy closely resemble those associated with aristolochic acid nephropathy except for the slower progression to end stage renal disease and longer cumulative period before the appearance of urothelial cancer. Recently, we reported the presence of AA-DNA adducts in renal cortex and A-->T p53 mutations in tumor tissue of patients from Croatia and Bosnia with endemic nephropathy. These data support the hypothesis that dietary exposure to AA is a major risk factor for endemic (Balkan) nephropathy.
Insights
Aristolochic acid (AA) exposure causes specific mutations in the TP53 gene, leading to upper urinary tract urothelial carcinoma. Dietary AA is a significant risk factor for Balkan endemic nephropathy and associated cancers.
Area of Science:
- Oncology
- Toxicology
- Genetics
Background:
- Carcinogenesis involves protooncogene activation and tumor suppressor gene inactivation.
- TP53 gene mutations are prevalent in over 50% of human cancers, often resulting in inactive p53 protein accumulation.
- Aristolochic acid (AA) is a nephrotoxin and carcinogen linked to aristolochic acid nephropathy and upper urinary tract urothelial carcinoma.
Purpose of the Study:
- To investigate the role of aristolochic acid (AA) in the etiology of endemic (Balkan) nephropathy.
- To examine the association between AA exposure, TP53 gene mutations, and urothelial carcinoma in patients with endemic nephropathy.
Main Methods:
- Analysis of AA-DNA adducts in renal cortex.
- Detection of TP53 gene mutations in tumor tissues from patients with endemic nephropathy.
- Comparison of clinical and pathological features with aristolochic acid nephropathy.
Main Results:
- AA exposure is associated with a high frequency of A-->T transversions in the TP53 gene.
- AA-DNA adducts and TP53 mutations were found in patients with endemic nephropathy from Croatia and Bosnia.
- Endemic nephropathy shares pathological similarities with AA nephropathy, suggesting a common causative agent.
Conclusions:
- Dietary exposure to aristolochic acid (AA) is a major risk factor for endemic (Balkan) nephropathy.
- AA-induced TP53 mutations contribute to the development of urothelial carcinoma in endemic nephropathy patients.
Related Concept Videos
Abnormal Proliferation
Mutagenicity and Carcinogenicity
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

